Shanghai, China, 24 January 2025 - The FireRaptor® Integrated Coronary Rotational Atherectomy System, including the FireRaptor® Coronary Rotational Atherectomy Console, the FireRaptor® Coronary Atherectomy Catheter, and the FireRaptor® Coronary Atherectomy Guidewire, developed by MicroPort® RotaPace, has officially received market approval in China.
Severe coronary calcified lesions present significant challenges in interventional cardiology, often reducing procedural success rates and impacting patient outcomes. Rotational atherectomy plays a critical role in addressing these challenges by modifying hard calcified plaques, facilitating device passage, and optimizing stent deployment.
FireRaptor® offers an innovative solution for treating moderate to severe calcified coronary lesions. Its eccentric, diamond-coated burr allows operators to adjust rotational speed, enabling precise control of the ablation diameter and minimizing the need for device exchanges. The diamond coating, applied across the entire burr surface, further supports radial bidirectional atherectomy, reducing the risk of burr entrapment and enhancing procedural safety.
The approval of FireRaptor® represents a significant milestone for MicroPort® in advancing the treatment of resistant coronary lesions. Combined with the Scoring Balloon and the Coronary Shockwave Catheter System, FireRaptor® provides interventional cardiologists with a comprehensive solution for addressing complex coronary lesions.
About MicroPort® RotaPace
Founded in 2020, MicroPort® RotaPace (Shanghai MicroPort RotaPace MedTech Co., Ltd.), an associated company of MicroPort® Coronary (Shanghai MicroPort Medical (Group) Co., Ltd.), is an innovative high-end medical device company focusing on the R&D, manufacturing, and commercialization of panvascular access interventional devices. MicroPort® RotaPace pioneers new advancements in cardiovascular interventional active medical devices, prioritizing innovations for complex PCI surgeries and post-PCI recovery, further expanding its interventional cardiovascular treatment portfolio.